What is Leerink Partnrs' Estimate for Climb Bio Q2 Earnings?

Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Leerink Partnrs upped their Q2 2025 EPS estimates for Climb Bio in a report issued on Tuesday, March 25th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($0.15) per share for the quarter, up from their previous forecast of ($0.16). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio's FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($1.10) EPS, FY2028 earnings at ($1.73) EPS and FY2029 earnings at ($2.69) EPS.

Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02.

Separately, Leerink Partners started coverage on Climb Bio in a research note on Monday, December 2nd. They set an "outperform" rating and a $10.00 target price on the stock.

Climb Bio Stock Up 2.5 %

CLYM traded up $0.03 during midday trading on Friday, reaching $1.25. 89,911 shares of the company's stock traded hands, compared to its average volume of 358,444. Climb Bio has a 52 week low of $1.20 and a 52 week high of $11.55. The firm has a fifty day moving average price of $1.53. The company has a market cap of $84.34 million, a PE ratio of -0.59 and a beta of -0.19.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.